STOCK TITAN

Emergent BioSolutions Inc. - EBS STOCK NEWS

Welcome to our dedicated page for Emergent BioSolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent BioSolutions stock.

Emergent BioSolutions, Inc. (NYSE: EBS) is a global life sciences company dedicated to protecting and enhancing life. With a mission to secure public health, Emergent develops, manufactures, and distributes a broad portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company is committed to safeguarding lives and aims to protect and enhance 50 million lives with its products by 2025.

Headquartered in Gaithersburg, Maryland, Emergent operates through three primary segments: Commercial, Products, and Services. The Commercial segment, which generates the majority of the company's revenue, includes key products such as NARCAN® Nasal Spray—a life-saving medication for opioid overdoses. NARCAN® has become widely accessible in pharmacies, grocery stores, and online retailers, significantly increasing public availability since its over-the-counter approval by the FDA in March 2023.

Emergent is also known for its role in developing and manufacturing vaccines and therapeutics, particularly for governments and healthcare providers. The company's Baltimore Bayview manufacturing facility recently received a “No Action Indicated” status from the FDA, confirming its compliance with good manufacturing practices. This recognition underscores Emergent's dedication to quality and compliance in its manufacturing processes.

Financially, Emergent is focused on stabilizing its operations and strengthening its balance sheet. The recent restructuring plan aims to streamline operations, close certain manufacturing facilities, and reduce workforce by 300 employees, resulting in annualized savings of approximately $80 million. Despite these changes, Emergent remains dedicated to its core business areas and continues to offer integrated contract development and manufacturing services to pharmaceutical and biotechnology customers.

Key recent developments include the extension of NARCAN® Nasal Spray's shelf life from 36 to 48 months and its widespread distribution across the U.S. and Canada. Emergent is also actively working with partners like the National Safety Council to educate businesses and the public about opioid overdose prevention and response.

Emergent is committed to its long-term vision of protecting and enhancing 1 billion lives by 2030. The company continues to innovate and expand its product offerings while maintaining a strong focus on public health and safety.

Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) is dedicated to combating the opioid crisis by expanding access to NARCAN® Nasal Spray, the first FDA-approved over-the-counter naloxone. With millions of doses distributed in 2023 and availability in over 32,000 retail locations, Emergent aims to address the increasing demand for opioid overdose reversal medications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) receives 'No Action Indicated' status from the FDA for its Baltimore Bayview manufacturing facility, indicating compliance with cGMP. The company emphasizes its dedication to quality, compliance, and delivering high-quality products to customers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
none
-
Rhea-AI Summary
Emergent BioSolutions Inc. reported Q4 2023 Total Revenues of $277 million, aligning Full Year 2023 revenues to $1.05 billion. Despite a Net Loss of $50 million in Q4 2023, the company remains optimistic about its future. Key highlights include the launch of NARCAN® Naloxone HCl Nasal Spray 4 mg Over-The-Counter, FDA approval of CYFENDUS®, and significant contract awards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.03%
Tags
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on March 6, 2024, to discuss financial results for Q4 and full year 2023. Newly appointed CEO Joseph C. Papa will provide remarks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. appoints Joseph C. Papa as president and CEO to focus on public health protection, growth, and debt reduction. The company highlights key achievements in 2023, including product launches, FDA approvals, and financial improvements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.29%
Tags
management acquisition
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) secures a $235.8 million contract with the U.S. Department of Defense to supply BioThrax for anthrax prevention. The contract includes a five-year base agreement and an additional five-year option, highlighting the importance of Emergent's medical countermeasures portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences acquisition
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) receives a $75 million contract option from BARDA for newly licensed anthrax vaccine CYFENDUS™. The vaccine was approved by the FDA in July 2023 and is aimed at addressing the national security threat posed by anthrax. Deliveries are expected to be completed by the end of the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) received a notice from the NYSE regarding non-compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the SEC. Emergent has six months to file the Form 10-Q and regain compliance. The company is working to quantify and evaluate the impact of past period state deferred tax liability and income tax benefits on its reporting, which is affecting its ability to provide a complete estimate of its results of operations for the three- and nine-month periods ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) reported Q3 2023 total revenues of $271M, a pre-tax loss of $(266)M, and adjusted EBITDA of $20M. The company updated its FY 2023 guidance. Key highlights include FDA approval of CYFENDUSTM, a 10-year contract for EbangaTM, and the over-the-counter launch of NARCAN® Nasal Spray. The company also completed the FDA inspection of its Camden facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags

FAQ

What is Emergent BioSolutions' core mission?

Emergent BioSolutions' core mission is to protect and enhance life by developing, manufacturing, and delivering medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

What are the main segments of Emergent BioSolutions?

Emergent operates through three main segments: Commercial, Products, and Services. The Commercial segment, including products like NARCAN® Nasal Spray, generates the majority of the company's revenue.

What is NARCAN® Nasal Spray?

NARCAN® Nasal Spray is a life-saving medication used to reverse opioid overdoses. It has been widely distributed in pharmacies, grocery stores, and online retailers since its over-the-counter approval by the FDA in March 2023.

What recent compliance certification did Emergent receive?

Emergent's Baltimore Bayview manufacturing facility received a “No Action Indicated” status from the FDA, indicating compliance with current good manufacturing practices.

What are Emergent's recent restructuring plans?

Emergent has initiated a restructuring plan that includes closing several manufacturing facilities and reducing its workforce by approximately 300 employees, aiming for annualized savings of about $80 million.

How is Emergent enhancing the availability of NARCAN® Nasal Spray?

Emergent has extended the shelf life of NARCAN® Nasal Spray from 36 to 48 months and distributed it widely across the U.S. and Canada. They are also partnering with organizations like the National Safety Council to raise awareness and improve access.

What financial goals does Emergent have?

Emergent aims to stabilize its financial position by improving operational efficiency and managing debt. They are focused on achieving annualized savings of approximately $80 million through their restructuring plan.

What is Emergent's vision for the future?

Emergent envisions protecting and enhancing 1 billion lives by 2030 through their innovative medical countermeasures and public health products.

What services does Emergent offer to pharmaceutical and biotechnology customers?

Emergent offers integrated contract development and manufacturing services, including the development and production of vaccines and therapeutics for complex public health threats.

How can stakeholders participate in Emergent's conference calls?

Stakeholders can access Emergent's conference calls via live webcast or telephone by registering in advance. Detailed instructions and a unique passcode are provided upon registration.

Emergent BioSolutions Inc.

NYSE:EBS

EBS Rankings

EBS Stock Data

558.08M
52.40M
2.16%
69.96%
12.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG